Gladstone NOW: The Campaign Join Us on the Journey ✕
1066 - 1080 of 1392 Results Clear All
Bay Area philanthropist leaves a legacy as a long-time friend and supporter of the Gladstone Institutes.
Institutional News
Bay Area scientists gathered to learn about the latest advances in mass spectrometry.
Krogan Lab
Gladstone scientists are mapping the connections and functions of brain cells to identify new drug targets to treat psychiatric disorders.
Kreitzer Lab Krogan Lab CRISPR/Gene Editing
The NINDS award provides longer-term support and increased flexibility to pursue innovative, high-risk research on neurological diseases.
Multiple Sclerosis Akassoglou Lab
Thomas Packard, a postdoctoral scholar at Gladstone, talks about his life-long passion for science and how Gladstone's reputation as a top place to do a postdoctoral fellowship led him to the Greene laboratory.
Greene Lab
Anti-cancer drug prevented less weight gain and caused mice to burn more calories thanks to higher levels of metabolism-boosting brown fat.
Ding Lab Metabolism Diabetes
Gladstone hosted a reception for attendees of the 35th annual J.P. Morgan Healthcare Conference to discuss scientific discoveries, partnering opportunities, and investment strategies involving Gladstone’s research.
Corporate Liaison and Ventures
Scientists discover an enzyme that that could be targeted to treat both Alzheimer’s disease and frontotemporal dementia.
Alzheimer’s Disease Finkbeiner Lab
Scientists from the Gladstone Institutes will team up with other national experts to better understand frontotemporal dementia.
Gan Lab
New details learned about a key cellular protein could lead to treatments for neurodegenerative diseases, such as Parkinson’s, Huntington’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS).
Finkbeiner Lab
Chris Goodfellow shares how his love of motorcycles has influenced his path to Gladstone and fueled his passion for traveling.
Profile
Research on a gene mutation that causes holes in the hearts of infants revealed insights into how the heart develops and how it stays healthy.
Heart Failure Congenital Heart Disease Srivastava Lab
Katherine Pollard’s expertise, success, and vision fueled her promotion to director of Gladstone’s Convergence Zone.
Pollard Lab
A new biopharmaceutical company, Tenaya Therapeutics Inc., will build on discoveries in cardiovascular disease research made at the Gladstone Institutes, concentrating on regenerative medicine and drug discovery for heart failure.
Institutional News News Release Heart Failure
Anatol Kreitzer was unanimously selected based on his experience training graduate students and his vision for the future.
Kreitzer Lab
